Boston, MA, United States of America

Natarajan Sethuraman

USPTO Granted Patents = 2 

Average Co-Inventor Count = 5.0

ph-index = 1

Forward Citations = 3(Granted Patents)


Company Filing History:


Years Active: 2021-2024

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Natarajan Sethuraman: Innovator in Mitochondrial Research

Introduction

Natarajan Sethuraman is a prominent inventor based in Boston, MA (US). He has made significant contributions to the field of mitochondrial research, particularly in the treatment of mitochondrial neurogastrointestinal encephalopathy syndrome (MNGIE). With a total of 2 patents, his work is paving the way for innovative therapeutic approaches.

Latest Patents

Sethuraman's latest patents focus on compositions and methods for treating MNGIE. These patents disclose compounds that possess cell-penetrating activity and thymidine phosphorylase activity. In certain embodiments, the compounds include at least one cell-penetrating peptide (CPP) moiety and a thymidine phosphorylase or an active fragment or analog thereof. The CPP is coupled, either directly or indirectly, to the thymidine phosphorylase, enhancing the potential for effective treatment.

Career Highlights

Natarajan Sethuraman is currently associated with Entrada Therapeutics, Inc., where he continues to advance his research in mitochondrial diseases. His innovative approaches and dedication to improving patient outcomes have established him as a key figure in his field.

Collaborations

Sethuraman collaborates with notable colleagues such as Jason Ruth and Dehua Pei. Their combined expertise contributes to the development of groundbreaking therapies in mitochondrial research.

Conclusion

Natarajan Sethuraman's work in the field of mitochondrial neurogastrointestinal encephalopathy is noteworthy. His innovative patents and collaborations are instrumental in advancing treatment options for this challenging condition.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…